Accessibility StatementSkip Navigation AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma NORTH CHICAGO, Ill., Nov. 24, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025. Management will participate in a fireside chat at 7:30 a.m. Central time. A live audio webcast of the presentation will be accessible thro ...

Core Insights - Financial giants are showing a bearish sentiment towards AbbVie, with 33% of traders indicating bearish tendencies compared to 11% bullish [1] - Significant investors are targeting a price range for AbbVie between $100.0 and $260.0 over the past three months [2] - AbbVie has a diverse portfolio in immunology and oncology, bolstered by recent acquisitions [8] Trading Activity - Recent options activity for AbbVie includes 9 unusual trades, with 4 puts valued at $326,123 and 5 calls valued at $230,186 [1] - The largest observed options trades include neutral sentiment for puts and bullish sentiment for certain calls, with notable strike prices [7] Analyst Ratings - Analysts have varying target prices for AbbVie, with an average target of $251.0 and individual targets ranging from $220 to $289 [10][11] - JP Morgan maintains an Overweight rating with a target price of $260, while UBS and Citigroup hold Neutral ratings with targets of $220 and $235 respectively [11] Current Performance - AbbVie’s stock price is currently at $229.06, reflecting a decrease of 1.65% with a trading volume of 1,945,474 [13] - The next earnings report for AbbVie is scheduled in 71 days, and current RSI values indicate a neutral position [13]

Company Highlights - Viking Therapeutics has completed enrollment of approximately 4,650 adults in the phase III VANQUISH-1 study for its obesity drug VK2735, surpassing its initial target of 4,500 patients [2][3][9] - The study evaluates the safety and efficacy of three subcutaneous dosing arms (7.5 mg, 12.5 mg, and 17.5 mg) against a placebo, with a primary endpoint of percent change in body weight after 78 weeks [2][9] - The company is also enrolling patients in the phase III VANQUISH-2 study, targeting nearly 1,100 obese or overweight adults with type II diabetes, with expected completion in Q1 2026 [5] Industry Context - The obesity market is projected to reach $100 billion in the United States by 2030, driven by the success of existing drugs from Eli Lilly and Novo Nordisk [11] - Both companies are actively developing new oral weight-loss medications, with Novo Nordisk seeking FDA approval for an oral version of Wegovy by the end of this year [12] - Pfizer has re-entered the obesity market by acquiring Metsera for around $10 billion, adding four novel clinical-stage programs to its portfolio, which could generate significant peak sales [15]

Summary of Aldeyra Therapeutics Conference Call Company Overview - **Company**: Aldeyra Therapeutics (NasdaqCM:ALDX) - **Industry**: Biopharmaceuticals, specifically focusing on immunology and ocular diseases Key Points and Arguments 1. **Lead Asset and Upcoming Milestones**: Aldeyra is preparing for an FDA decision on its lead asset reproxalap for dry eye disease, with a PDUFA date set for December 16, 2025 [4][18][24] 2. **Resubmission of NDA**: The company resubmitted its New Drug Application (NDA) in June 2025 after addressing a Complete Response Letter (CRL) from the FDA, which required an additional trial due to a baseline imbalance [8][9][10] 3. **Clinical Trials and Data**: The recent NDA package included data from a symptom trial that showed no baseline imbalance, which is crucial for FDA approval. The trials assess both symptoms and signs of dry eye disease [12][14][16] 4. **Commercialization Strategy**: Aldeyra has an option agreement with AbbVie, which includes a $100 million opt-in fee after approval, and a revenue-sharing model of 60% to AbbVie and 40% to Aldeyra [20][21][23] 5. **Market Opportunity**: There are approximately 40 million people in the U.S. suffering from dry eye disease, with only 5%-10% currently treated. The market is expected to grow due to increased awareness and more available therapies [24][25] 6. **Allergic Conjunctivitis Program**: Reproxalap is also being developed for allergic conjunctivitis, which is a significant market opportunity. The company has conducted phase three trials showing improvements in redness and itching [25][27] 7. **RASP Pipeline**: Aldeyra is prioritizing next-generation RASP modulators ADX-248 and ADX-246, which are designed to target multiple proteins and have better pharmacokinetics compared to reproxalap [30][31] 8. **Preclinical Data**: The company is exploring the use of RASP modulators in neurological diseases such as Parkinson's and ALS, indicating a potential expansion into central nervous system disorders [34][35] 9. **Ocular Lymphoma and Retinitis Pigmentosa**: Aldeyra is working on a pivotal trial for ocular lymphoma using a new formulation of methotrexate and has shown promising results in retinitis pigmentosa, a rare disease with no current broad therapy [38][39][40] 10. **Dry AMD and Geographic Atrophy**: The company aims to assess the impact of its treatments on night vision in patients with dry AMD, focusing on patient-reported outcomes rather than just lesion size [41][42] Additional Important Information - **Regulatory Environment**: The FDA review process is described as quiet, with no significant delays anticipated due to recent government shutdowns [18] - **Commercial Preparation**: AbbVie is actively preparing for the potential launch of reproxalap, leveraging its experience in the dry eye market [23][24] - **Future Directions**: Aldeyra plans to diversify its pipeline across various indications and stages, with a focus on both ocular and neurological diseases [43][44]

Core Insights - Johnson & Johnson's stock price has increased over 7% since the beginning of November, driven by strong third-quarter results that exceeded Wall Street expectations [1] - The company reported nearly 7% sales growth year-over-year, reaching $24 billion, and adjusted earnings per share rose 15.7% to $2.80, surpassing consensus estimates [1] - J&J raised its full 2025 revenue growth guidance to 5.7% over 2024, indicating management's optimism [1] Business Strategy - J&J plans to spin off its slow-growing orthopedics group within two years, focusing instead on its faster-growing cardiovascular and surgery businesses [2] - The acquisition of Halda Therapeutics for $3.05 billion aims to enhance J&J's oncology portfolio, particularly in prostate cancer treatments [4] Market Response - The market reacted positively to the Halda acquisition announcement, as the biotech has a promising drug in early-stage trials for metastatic prostate cancer [7] - J&J's oncology and immunology drugs face competition, particularly from AbbVie, making the acquisition strategically important [5] Industry Context - The expiration of the patent for J&J's immunology drug Stelara highlights the urgency for the company to renew its drug pipeline through acquisitions [6] - Prostate cancer is a significant health concern, with new diagnoses expected to reach 1.7 million globally by 2030, underscoring the importance of J&J's new drug developments [9]

Core Viewpoint - The article emphasizes the importance of dividend stocks as a reliable investment strategy during market volatility, highlighting AbbVie and Realty Income as two strong candidates for income-focused investors [3][5][13]. Company Summaries AbbVie (ABBV) - AbbVie has shown significant stock performance, with a year-to-date increase of 36% and a 187% rise over the last five years [4][8]. - The company offers an annual dividend of $6.92, resulting in a yield of 2.96%, making it attractive for income investors [7][8]. - AbbVie maintains a strong cash flow supported by a diversified drug pipeline in immunology, neuroscience, and oncology, which enhances its stability during market downturns [9][14]. Realty Income (O) - Realty Income, known as "The Monthly Dividend Company," has raised its dividend for 21 consecutive years, showcasing its reliability [10][11]. - The current dividend yield stands at 5.64%, with annual payouts of $3.21, appealing to investors seeking consistent income [11]. - The company's business model, based on long-term net lease agreements, provides predictable revenue and resilience against economic downturns [11][12]. Investment Strategy - Both AbbVie and Realty Income operate in different sectors but together create a balanced foundation for investors looking for passive income [13][14]. - AbbVie provides exposure to the healthcare sector with strong cash generation, while Realty Income offers monthly income through reliable long-term contracts [14].

Summary of Option Care Health Conference Call Company Overview - **Company**: Option Care Health (NasdaqGS: OPCH) - **Industry**: Healthcare Services, specifically home and alternate site infusion therapy - **Key Operations**: - Largest independent provider of infusion services in the U.S. - Operates over 90 closed-door pharmacies and 170 infusion centers - Serves over 300,000 unique patients annually with a team of approximately 8,000, including 4,500 clinicians [4][6] Core Business Insights - **Market Position**: - Well-positioned to capitalize on changes in competitive dynamics, especially as some competitors exit the market for acute patients [7][8] - Focus on local responsiveness while leveraging national scale as a competitive advantage [7][8] - **Product Portfolio**: - Expanding offerings in chronic conditions and limited distribution drugs [8] - Notable product: Stelara, which is facing headwinds due to biosimilars and changes in discount structures [9][10] Financial Guidance and Challenges - **Stelara Impact**: - Expected financial impact of $60 million to $70 million in 2025 due to reduced discounts and market changes [9][10] - Ongoing negotiations with Janssen to manage pricing and patient transitions to biosimilars [12][13] - **Growth Expectations**: - Anticipated mid-teens growth in acute therapy business, with expectations to maintain market share despite industry trends [22][23] - Chronic therapy growth expected to be lower due to biosimilar transitions, with projections in the low double digits [24][25] - **EBITDA and Revenue Projections**: - Confidence in continued growth in revenue, adjusted EBITDA, and adjusted EPS through 2026, despite headwinds from Stelara [30][33] Strategic Initiatives - **Advanced Practitioner Model**: - Aimed at expanding access to patients and enhancing care quality [37][38] - Increased efficiency in nursing visits, with 34% of visits occurring in infusion suites, up from 17% [39] - **Capital Deployment Strategy**: - Focus on investing in business growth, including CapEx for technology and facilities, while remaining disciplined in M&A and share buybacks [40][41] Market Dynamics and Future Outlook - **Competitive Landscape**: - Anticipation of a shift towards biosimilars and lower-cost settings, creating opportunities for Option Care Health [20][21] - Long-term belief in high single-digit top-line growth and low double-digit bottom-line growth post-2026 [35][36] - **Commitment to Shareholders**: - Strong cash flow management and commitment to delivering on financial promises, with significant share buybacks already executed [40][41]

Core Insights - AbbVie reported third-quarter 2025 results, beating estimates for both earnings and sales, with sales increasing by 9.1% year over year, while earnings declined by 38% due to acquisition-related costs [1][9] - The company raised its revenue and EPS guidance for 2025 for the third time this year, supported by strong year-to-date momentum [1] Sales Performance - AbbVie's stock initially declined post-earnings release due to softer sales in oncology drugs and ongoing weakness in the Aesthetics unit, but later recovered and crossed the 50-day moving average [2] - Sales of AbbVie's ex-Humira drugs rose over 20% in Q3, driven by strong performances from Skyrizi and Rinvoq, which generated combined sales of $18.5 billion in the first nine months of 2025 [24][4] Drug Portfolio - AbbVie successfully navigated the loss of exclusivity for Humira by launching new immunology drugs, Skyrizi and Rinvoq, which are expected to support top-line growth in the coming years [3][5] - Skyrizi is annualizing at almost $18 billion, while Rinvoq is at over $8 billion, with expectations to exceed combined sales of $25 billion in 2025 and $31 billion by 2027 [5] Oncology and Neuroscience Contributions - The oncology segment generated combined revenues of $5.0 billion in the first nine months of 2025, up 2.7% year over year, driven by higher sales of Venclexta and contributions from new drugs [7] - AbbVie's neuroscience portfolio saw a 20.3% increase in sales to nearly $7.8 billion, supported by higher sales of Botox Therapeutic and newer migraine drugs [8] Challenges and Adjustments - AbbVie is experiencing declining sales in its Aesthetics unit, with global sales down 0.6% in 2024 and 7.4% in the first nine months of 2025, attributed to macroeconomic challenges and low consumer sentiment [13][14] - The company lowered its expectations for the Aesthetics business from $5.1 billion to $4.9 billion due to greater-than-expected market softness [15] Financial Outlook - AbbVie stock has risen 31.6% year-to-date, outperforming the industry and S&P 500 [16] - The stock is reasonably priced with a forward P/E ratio of 16.74, lower than the industry average of 16.81 [19] - Despite recent estimate declines, AbbVie expects to return to mid-single-digit revenue growth in 2025, driven by robust performances from Skyrizi and Rinvoq [25][26]

Core Insights - EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific antibody combination therapy approved for patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapy [1] - In the Phase 3 EPCORE® FL-1 trial, EPKINLY + R2 showed significantly superior progression-free survival and overall response rates compared to the standard of care R2, with approximately 75% of patients achieving a complete response [1] - This approval marks the third indication for EPKINLY and the first-ever FDA approval for a bispecific combination therapy in lymphoma [1] Company Insights - AbbVie (NYSE: ABBV) announced the FDA approval of EPKINLY® (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma [1]

Core Insights - Genmab A/S announced FDA approval for EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma, based on the Phase 3 EPCORE FL-1 study results [2][7][9] Group 1: Study Results - EPKINLY + R reduced the risk of disease progression or death by 79% compared to standard treatment R, with a hazard ratio of 0.21 [3] - The median progression-free survival (PFS) was not reached for EPKINLY + R, while it was 11.2 months for R [3] - Among patients treated with EPKINLY + R, 89% responded to treatment and 74% achieved a complete response, compared to 74% overall response rate and 43% complete response rate for R [3] Group 2: Safety Profile - The safety profile of EPKINLY + R was consistent with known safety profiles of the individual components, with common adverse reactions including rash, upper respiratory infections, and fatigue [4] - Cytokine release syndrome (CRS) occurred in 24% of patients, primarily low grade, with a single event of immune effector cell-associated neurotoxicity syndrome (ICANS) reported [4][21] Group 3: Industry Impact - The approval of EPKINLY + R represents a significant advancement for patients with follicular lymphoma, providing a chemotherapy-free treatment option that can be administered in outpatient settings [5][6] - Follicular lymphoma is a slow-growing form of non-Hodgkin lymphoma affecting approximately 15,000 new patients annually in the U.S., with current therapies considered incurable [5][26] Group 4: Future Prospects - EPKINLY + R is the first bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line setting, marking the third indication for EPKINLY [7] - Genmab and AbbVie are continuing to evaluate epcoritamab in various hematologic malignancies, with multiple ongoing Phase 3 trials [29][28]